Search Results for keywords:"ASME B

The Bureau of Consumer Financial Protection has issued an Advisory Opinion to clarify rules under Regulation B of the Equal Credit Opportunity Act regarding special purpose credit programs. This opinion provides guidance to for-profit organizations on how to develop credit programs that serve specific social needs and explains what information must be included in programs' written plans. It aims to address regulatory uncertainties and encourage financial institutions to create programs that improve credit access for disadvantaged groups. The Advisory Opinion became effective on January 15, 2021.

S&B Pharma, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for manufacturing purposes and ANPP to produce other controlled substances, but they will not import finished products for commercial sale. Interested parties, such as registered manufacturers, can submit comments, objections, or request a hearing regarding this application by March 18, 2021.

S&B Pharma, Inc. has applied to the Drug Enforcement Administration to be registered as a bulk manufacturer of certain controlled substances. The company intends to produce these substances in large quantities for product development and commercial sales. Specifically, S&B Pharma plans to create synthetic versions of Marihuana and Tetrahydrocannabinols. The public and current registered manufacturers have until April 26, 2021, to submit comments or request a hearing on this application.

The Centers for Disease Control and Prevention (CDC) is asking for feedback on whether nurse practitioners and physician assistants should be allowed to take the NIOSH B Reader examination to be certified to assess chest radiographs for dust-induced lung diseases. Right now, only licensed physicians can become B Readers. The CDC wants input from health experts, industry, and workers on potential benefits and risks of this change, and how it might improve health monitoring across different areas and populations. They are accepting comments until March 17, 2025.

The General Services Administration (GSA) is issuing a notice to cancel a specific bulletin, FMR Bulletin B-2023-55, which was related to fleet management information systems and dated May 19, 2023. This action is being taken in response to Executive Orders 14148 and 14154, both issued on January 20, 2025. These new orders revoked an earlier order that aimed to promote clean energy and federal sustainability, leading to the rescission of the bulletin. The cancellation is effective from April 17, 2025.

The document provides a consolidated notice of all agency-specific excepted authorities, as approved by the Office of Personnel Management (OPM), under Schedules A, B, and C as of June 30, 2020. It details special rules that allow different government agencies to hire employees outside the typical competitive service process. The document includes specific exceptions for a variety of federal departments and agencies, outlining positions and criteria for employment under these exceptions. These exceptions are published annually in compliance with federal regulations.

The Securities and Exchange Commission (SEC) has requested approval from the Office of Management and Budget (OMB) to continue collecting information under Rule 17f-1(b) of the Securities Exchange Act of 1934. This rule involves the Lost and Stolen Securities Program, which requires approximately 9,500 entities to register and report securities issues like missing, lost, or stolen documents. The SEC estimates that four new entities will join the program each year, each taking about half an hour to comply, costing around $172 per entity annually. The public can comment on this information collection request from December 3, 2024, to January 2, 2025, through the provided online platform or email.

S&B Pharma LLC, also known as Norac Pharma, has submitted an application to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company plans to import these substances in bulk to manufacture other controlled drugs for its customers. The public can submit comments or request a hearing regarding this application until February 11, 2021. All submissions should be sent to the DEA offices in Springfield, Virginia.

S&B Pharma LLC DBA Norac Pharma has submitted an application to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for further manufacturing and ANPP for producing other controlled substances. Public comments or objections to this application can be submitted electronically by March 28, 2025. The DEA will only approve import permits if the company's activities comply with specific federal regulations.

The U.S. Department of Commerce has extended the Temporary Denial Order (TDO) against Siberian Airlines, also known as S7 Airlines, for another year. This decision is due to ongoing violations of U.S. export regulations by the airline, involving the operation of airplanes into Russia without proper authorization. The measure aims to prevent further violations, warn companies and individuals about dealing with Siberian Airlines, and uphold stringent export controls related to Russia's use of certain technologies. Siberian Airlines may appeal this order, and the Commerce Department can request further renewals of the TDO.